SOK583A1 (40 mg/mL)

BIOLOGICAL2 trials

Sponsors

Sandoz

Conditions

Neovascular Age-related Macular DegenerationNeovascular Age-related Macular Degeneration (nAMD)

Phase 3

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

CompletedNCT04864834

SandozNeovascular Age-related Macular Degeneration

Start: 2021-05-12End: 2023-05-10Updated: 2024-03-26

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

CompletedNCT05161806

SandozNeovascular Age-related Macular Degeneration (nAMD)

Start: 2022-03-11End: 2022-05-04Updated: 2022-11-18